Perioperative Nivolumab Significantly Improves EFS in Previously Untreated Resectable NSCLC

Neoadjuvant treatment with nivolumab plus chemotherapy followed by surgery and adjuvant nivolumab resulted in a statistically significant improvement in event-free survival vs placebo plus chemotherapy, in patients with previously untreated resectable stage II to IIIB non-small cell lung cancer, according to data from the phase 3 CheckMate 77T trial.

Related Keywords

Texas ,United States , ,Department Of Thoracic ,University Of Texas Md Anderson Cancer Center ,Neck Medical Oncology ,Cancer Center ,Lung Cancer Treatment Research Enters ,Nivolumab ,Neoadjuvant Adjuvant Nivolumab ,Perioperative Nivolumab ,Immunotherapy ,Non Small Cell Lung Cancer ,Lung Cancer ,Nsclc ,Checkmate 77t ,